29 related articles for article (PubMed ID: 19622291)
1. Divergent synthetic nucleotide motif recognition pattern: design and development of potent immunomodulatory oligodeoxyribonucleotide agents with distinct cytokine induction profiles.
Kandimalla ER; Bhagat L; Wang D; Yu D; Zhu FG; Tang J; Wang H; Huang P; Zhang R; Agrawal S
Nucleic Acids Res; 2003 May; 31(9):2393-400. PubMed ID: 12711684
[TBL] [Abstract][Full Text] [Related]
2. Fully phosphorothioate-modified CpG ODN with PolyG motif inhibits the adhesion of B16 melanoma cells in vitro and tumorigenesis in vivo.
Wang X; Wang L; Wan M; Wu X; Yu Y; Wang L
Nucleic Acid Ther; 2013 Aug; 23(4):253-63. PubMed ID: 23848522
[TBL] [Abstract][Full Text] [Related]
3. NK cell activation and tumor infiltration are involved in the antitumor mechanism of Virulizin.
Cao MY; Lee Y; Feng N; Li H; Du C; Miao D; Li J; Lee V; Jin H; Wang M; Gu X; Wright JA; Young AH
Cancer Immunol Immunother; 2005 Mar; 54(3):229-42. PubMed ID: 15378281
[TBL] [Abstract][Full Text] [Related]
4. Immune cell-mediated antitumor activities of GD2-targeted liposomal c-myb antisense oligonucleotides containing CpG motifs.
Brignole C; Pastorino F; Marimpietri D; Pagnan G; Pistorio A; Allen TM; Pistoia V; Ponzoni M
J Natl Cancer Inst; 2004 Aug; 96(15):1171-80. PubMed ID: 15292389
[TBL] [Abstract][Full Text] [Related]
5. Antitumor therapy with bacterial DNA and toxin: complete regression of established tumor induced by liposomal CpG oligodeoxynucleotides plus interleukin-13 cytotoxin.
Ishii KJ; Kawakami K; Gursel I; Conover J; Joshi BH; Klinman DM; Puri RK
Clin Cancer Res; 2003 Dec; 9(17):6516-22. PubMed ID: 14695156
[TBL] [Abstract][Full Text] [Related]
6. Oligodeoxynucleotides containing CpG motifs can induce rejection of a neuroblastoma in mice.
Carpentier AF; Chen L; Maltonti F; Delattre JY
Cancer Res; 1999 Nov; 59(21):5429-32. PubMed ID: 10554011
[TBL] [Abstract][Full Text] [Related]
7. CpG oligodeoxynucleotide stimulates protective innate immunity against human renal cell carcinoma xenografted in nude mice.
Zhou PJ; Ma BB; He W; Xu D; Wang XH
J Immunother; 2011 Sep; 34(7):535-41. PubMed ID: 21760530
[TBL] [Abstract][Full Text] [Related]
8. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances anti-tumor responses of peripheral blood mononuclear cells from human lung cancer patients.
Ren T; Wen ZK; Liu ZM; Qian C; Liang YJ; Jin ML; Cai YY; Xu L
Cancer Invest; 2008 Jun; 26(5):448-55. PubMed ID: 18568766
[TBL] [Abstract][Full Text] [Related]
9. [Antitumor effect of CpG oligonucleotides on human neuroblastoma xenografts in nude mice].
Yao QH; Tang YJ; Gao FH; Tang JY
Ai Zheng; 2009 Apr; 28(4):344-9. PubMed ID: 19622291
[TBL] [Abstract][Full Text] [Related]
10. The immunobiology and clinical potential of immunostimulatory CpG oligodeoxynucleotides.
Weiner GJ
J Leukoc Biol; 2000 Oct; 68(4):455-63. PubMed ID: 11037965
[TBL] [Abstract][Full Text] [Related]
11. CpG oligonucleotides for immunotherapeutic treatment of neuroblastoma.
Miles SA; Sandler AD
Adv Drug Deliv Rev; 2009 Mar; 61(3):275-82. PubMed ID: 19186194
[TBL] [Abstract][Full Text] [Related]
12. Use of CpG oligodeoxynucleotides as immunoprotective agents.
Klinman DM
Expert Opin Biol Ther; 2004 Jun; 4(6):937-46. PubMed ID: 15174975
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
